High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for Resistant Osteomedullary Neuroblastoma: Major Responses and Outpatient Treatment in a Phase II Trial Meeting Abstract
| Authors: | Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K. |
| Abstract Title: | High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for Resistant Osteomedullary Neuroblastoma: Major Responses and Outpatient Treatment in a Phase II Trial |
| Meeting Title: | 52nd Congress of the International Society of Paediatric Oncology (SIOP) |
| Journal Title: | Pediatric Blood and Cancer |
| Volume: | 67 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Oct 14-17 |
| Meeting Location: | Virtual |
| ISSN: | 1545-5009 |
| Publisher: | Wiley Periodicals, Inc |
| Date Published: | 2020-12-01 |
| Start Page: | S32 |
| Language: | English |
| ACCESSION: | WOS:000581769200058 |
| PROVIDER: | wos |
| PUBMED: | 33049088 |
| DOI: | 10.1002/pbc.28742 |
| Notes: | Meeting Abstract: 0056 / #863 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work